Drugs / H5 Astrakhan RNA Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07019883 | Jun 2025 → May 2026 | avian influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H5-Astrakhan RNA vaccine | “The primary objective is to assess the safety of two doses of H5 AC-Anhui RNA vaccine or H5-Astrakhan RNA vaccine administered intramuscularly in healthy adults (18-49 years).” NCT07019883 ↗ |
| Known as | H5 Astrakhan RNA | “The H5 Astrakhan RNA encodes the HA from the clade 2.3.4.4b A/Astrakhan/3212/2020 virus.” NCT07019883 ↗ |
| Modality | Messenger RNA (mRNA) | “The vaccine product consists of a monovalent nucleoside-modified mRNA that encodes a traditionally selected avian influenza HA.” NCT07019883 ↗ |
| Route | Intramuscular | “The primary objective is to assess the safety of two doses of H5 AC-Anhui RNA vaccine or H5-Astrakhan RNA vaccine administered intramuscularly in healthy adults (18-49 years).” NCT07019883 ↗ |